NURS 5433 Module 6 Musculoskeletal Exam Prep Document
| 2026/2027 Edition | 250 Verified Questions
NURS 5433 Module 6 Musculoskeletal Exam 2026-2027 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation guide for NURS 5433 Module 6 focuses on musculoskeletal
disorders and nursing management. It contains 250 verified questions covering anatomy,
pathophysiology, assessment, and interventions. Designed to ensure a 100% guarantee pass, this
resource aligns with the latest 2026/2027 academic standards and evidence-based practice guidelines.
Key Features:
Musculoskeletal anatomy and physiology
Common disorders: fractures, osteoarthritis, osteoporosis
Nursing assessment and diagnostic tests
Pharmacological and non-pharmacological interventions
Postoperative care and rehabilitation
Patient education and safety considerations
Updates for 2026:
- Updated to reflect 2026/2027 clinical practice guidelines
- Revised rationales with current evidence-based references
- Added new questions on emerging treatments and technologies
- Enhanced distractor explanations to clarify common misconceptions
- Reorganized content areas for improved study flow
Abstract:
This document provides a rigorous review of musculoskeletal nursing for NURS 5433 Module 6, integrating
foundational knowledge with clinical application. The 250 questions are meticulously crafted to mirror exam
complexity, covering bone physiology, joint disorders, trauma, and surgical interventions. Each question is
accompanied by detailed rationales that explain correct answers and analyze incorrect options, fostering deep
understanding. Emphasis is placed on nursing process, patient safety, and interdisciplinary collaboration. Updated
for the 2026/2027 academic year, this guide incorporates the latest evidence on pain management, mobility aids,
and fall prevention. It serves as an essential tool for students aiming to achieve a superior grade and excel in
clinical practice.
Keywords:
Musculoskeletal nursing, Fracture management, Osteoarthritis, Osteoporosis, Nursing assessment, Pharmacology,
Rehabilitation, Patient education
Answer Format:
Each question includes a correct answer with a detailed rationale explaining the underlying pathophysiology or
nursing principle. Incorrect options are analyzed to clarify common errors. Distractors are designed to test critical
thinking and clinical reasoning, with explanations that highlight why each option is correct or incorrect.
Compliance Checklist:
Aligned with 2026/2027 NURS 5433 curriculum objectives
References current evidence-based practice guidelines
Includes rationales for all answer choices
Covers all key musculoskeletal disorders and interventions
Page 1
, Designed to promote critical thinking and exam readiness
Verified for accuracy by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Anatomy and Physiology 1-40 Bone structure, joint types, muscle function, 16%
innervation
Common Musculoskeletal 41-100 Fractures, osteoarthritis, osteoporosis, 24%
Disorders rheumatoid arthritis, gout
Nursing Assessment and 101-150 Physical exam, imaging studies, lab tests, 20%
Diagnostics pain assessment
Pharmacological and 151-200 Analgesics, anti-inflammatories, DMARDs, 20%
Non-Pharmacological physical therapy, braces
Interventions
Perioperative and Rehabilitation 201-250 Pre-op teaching, post-op complications, 20%
Care mobility aids, discharge planning
Page 2
,Q1. A patient with a history of chronic kidney disease (CKD) stage 4 presents with acute-onset atraumatic
shoulder pain, swelling, and limited range of motion. Radiographs reveal chondrocalcinosis and evidence of
calcium pyrophosphate dihydrate (CPPD) crystal deposition. Synovial fluid analysis shows positively
birefringent rhomboid crystals under polarized light microscopy. Which of the following best explains the
underlying pathophysiology of this presentation?
A. Uric acid crystal deposition due to impaired renal excretion leading to monosodium urate crystals
B. Calcium pyrophosphate crystal deposition facilitated by altered calcium and pyrophosphate metabolism in
CKD
C. Hydroxyapatite crystal deposition secondary to secondary hyperparathyroidism from CKD
D. Basic calcium phosphate crystal deposition due to elevated serum phosphate levels
Correct Answer: B. Calcium pyrophosphate crystal deposition facilitated by altered calcium and
pyrophosphate metabolism in CKD
Rationale: CPPD deposition disease (pseudogout) is associated with conditions like CKD, hyperparathyroidism,
and hemochromatosis. In CKD, reduced renal clearance of pyrophosphate leads to elevated levels, promoting
calcium pyrophosphate crystal formation. Option A describes gout (monosodium urate crystals, negatively
birefringent). Option C refers to hydroxyapatite deposition, often seen in calcific tendinitis. Option D is incorrect;
basic calcium phosphate crystals are not typically associated with CKD.
Why Wrong:
A - Uric acid crystals are negatively birefringent and associated with gout, not CPPD.
C - Hydroxyapatite crystals are not typically seen in CKD-related pseudogout.
D - Basic calcium phosphate crystals are associated with Milwaukee shoulder, not CKD.
Reference: Firestein, G.S., et al. (2021). Kelley & Firestein's Textbook of Rheumatology, 11th Ed., Ch. 107.
Q2. A patient with rheumatoid arthritis (RA) currently on methotrexate 20 mg weekly and sulfasalazine 2 g
daily continues to have 6 swollen and 8 tender joints, morning stiffness >1 hour, and an elevated CRP. The
patient has no history of tuberculosis or hepatitis. According to current ACR guidelines for RA management,
which of the following is the most appropriate next step?
A. Add hydroxychloroquine 400 mg daily
B. Switch from methotrexate to leflunomide 20 mg daily
C. Add a tumor necrosis factor (TNF) inhibitor such as adalimumab
D. Increase methotrexate dose to 25 mg weekly and continue sulfasalazine
Correct Answer: C. Add a tumor necrosis factor (TNF) inhibitor such as adalimumab
Rationale: The patient has moderate-to-high disease activity despite combination conventional synthetic DMARDs
(csDMARDs). Current ACR guidelines recommend adding a biologic DMARD (bDMARD), such as a TNF
inhibitor, in patients with inadequate response to csDMARDs. Option A would be appropriate for mild disease.
Option B is a switch within csDMARDs, but the patient has already failed combination therapy. Option D is
reasonable but the patient is already on a moderate dose; increasing methotrexate may not suffice.
Why Wrong:
A - Hydroxychloroquine is typically used for mild RA or in early disease, not after failure of combination
csDMARDs.
B - Switching to another csDMARD is less effective than adding a bDMARD in moderate-to-high disease
activity.
D - Increasing methotrexate is an option but less likely to achieve remission compared to adding a bDMARD.
Reference: Singh, J.A., et al. (2021). 2021 American College of Rheumatology Guideline for the Treatment of
Rheumatoid Arthritis. Arthritis Care & Research.
Page 3
, Q3. A patient with a history of osteoporosis, on denosumab 60 mg every 6 months for the past 3 years,
presents with a low-trauma vertebral compression fracture. Dual-energy x-ray absorptiometry (DXA) shows
a T-score of -3.2 at the lumbar spine, unchanged from 2 years ago. Which of the following is the most
appropriate management?
A. Continue denosumab and add teriparatide 20 mcg daily
B. Switch from denosumab to zoledronic acid 5 mg annually
C. Continue denosumab and add raloxifene 60 mg daily
D. Discontinue denosumab and start romosozumab 210 mg monthly
Correct Answer: A. Continue denosumab and add teriparatide 20 mcg daily
Rationale: The patient has sustained a fragility fracture despite denosumab therapy with stable BMD. Adding teriparatide (an
anabolic agent) to ongoing denosumab is recommended to improve bone strength. Option B is not indicated as denosumab has
not failed; switching to zoledronic acid may be considered if denosumab is discontinued, but the fracture occurred on therapy.
Option C: raloxifene is for vertebral fracture prevention in postmenopausal women but not for treatment of fracture on
therapy. Option D: romosozumab is an anabolic agent but is not typically added to denosumab; it is used as initial therapy in
high-risk patients.
Why Wrong:
B - Switching to zoledronic acid is not indicated as the patient is stable on denosumab; the fracture suggests need for
additional therapy.
C - Raloxifene is not indicated for treatment of fracture in patients already on denosumab.
D - Romosozumab is not typically used as add-on to denosumab; it is an initial therapy for high-risk patients.
Reference: Camacho, P.M., et al. (2020). American Association of Clinical Endocrinologists/American College of
Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis.
Endocrine Practice.
Q4. A patient with a history of type 2 diabetes and peripheral neuropathy presents with a painless, swollen,
and erythematous right foot after a minor twist. X-ray shows subtle osteopenia and joint space narrowing in
the midfoot, but no fracture. MRI reveals bone marrow edema and subchondral cysts in the tarsometatarsal
joints. Which of the following is the most likely diagnosis?
A. Septic arthritis of the midfoot
B. Charcot neuroarthropathy (neuropathic osteoarthropathy)
C. Acute gout flare involving the midfoot
D. Stress fracture of the metatarsals
Correct Answer: B. Charcot neuroarthropathy (neuropathic osteoarthropathy)
Rationale: Charcot neuroarthropathy is a progressive degenerative condition seen in patients with peripheral
neuropathy, often diabetes. It presents with a painless, swollen, erythematous foot, and MRI findings of bone
marrow edema, subchondral cysts, and joint destruction. Septic arthritis (A) typically presents with severe pain and
systemic signs. Gout (C) is usually painful and associated with hyperuricemia. Stress fracture (D) would show a
fracture line on imaging.
Why Wrong:
A - Septic arthritis is painful and associated with systemic signs; MRI would show joint effusion and abscess.
C - Gout is painful and typically has elevated uric acid; MRI findings differ.
D - Stress fracture would show a fracture line, not subchondral cysts.
Reference: Rogers, L.C., et al. (2020). The Charcot Foot: A Practical Guide. Journal of the American Podiatric
Medical Association.
Q5. A patient presents with acute onset of severe low back pain radiating to the left buttock and posterior
thigh. Straight leg raise test is positive on the left at 30 degrees. Neurologic exam reveals decreased sensation
over the lateral left foot and ankle, and mild weakness of left ankle plantarflexion. Which nerve root is most
likely affected?
Page 4
| 2026/2027 Edition | 250 Verified Questions
NURS 5433 Module 6 Musculoskeletal Exam 2026-2027 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation guide for NURS 5433 Module 6 focuses on musculoskeletal
disorders and nursing management. It contains 250 verified questions covering anatomy,
pathophysiology, assessment, and interventions. Designed to ensure a 100% guarantee pass, this
resource aligns with the latest 2026/2027 academic standards and evidence-based practice guidelines.
Key Features:
Musculoskeletal anatomy and physiology
Common disorders: fractures, osteoarthritis, osteoporosis
Nursing assessment and diagnostic tests
Pharmacological and non-pharmacological interventions
Postoperative care and rehabilitation
Patient education and safety considerations
Updates for 2026:
- Updated to reflect 2026/2027 clinical practice guidelines
- Revised rationales with current evidence-based references
- Added new questions on emerging treatments and technologies
- Enhanced distractor explanations to clarify common misconceptions
- Reorganized content areas for improved study flow
Abstract:
This document provides a rigorous review of musculoskeletal nursing for NURS 5433 Module 6, integrating
foundational knowledge with clinical application. The 250 questions are meticulously crafted to mirror exam
complexity, covering bone physiology, joint disorders, trauma, and surgical interventions. Each question is
accompanied by detailed rationales that explain correct answers and analyze incorrect options, fostering deep
understanding. Emphasis is placed on nursing process, patient safety, and interdisciplinary collaboration. Updated
for the 2026/2027 academic year, this guide incorporates the latest evidence on pain management, mobility aids,
and fall prevention. It serves as an essential tool for students aiming to achieve a superior grade and excel in
clinical practice.
Keywords:
Musculoskeletal nursing, Fracture management, Osteoarthritis, Osteoporosis, Nursing assessment, Pharmacology,
Rehabilitation, Patient education
Answer Format:
Each question includes a correct answer with a detailed rationale explaining the underlying pathophysiology or
nursing principle. Incorrect options are analyzed to clarify common errors. Distractors are designed to test critical
thinking and clinical reasoning, with explanations that highlight why each option is correct or incorrect.
Compliance Checklist:
Aligned with 2026/2027 NURS 5433 curriculum objectives
References current evidence-based practice guidelines
Includes rationales for all answer choices
Covers all key musculoskeletal disorders and interventions
Page 1
, Designed to promote critical thinking and exam readiness
Verified for accuracy by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Anatomy and Physiology 1-40 Bone structure, joint types, muscle function, 16%
innervation
Common Musculoskeletal 41-100 Fractures, osteoarthritis, osteoporosis, 24%
Disorders rheumatoid arthritis, gout
Nursing Assessment and 101-150 Physical exam, imaging studies, lab tests, 20%
Diagnostics pain assessment
Pharmacological and 151-200 Analgesics, anti-inflammatories, DMARDs, 20%
Non-Pharmacological physical therapy, braces
Interventions
Perioperative and Rehabilitation 201-250 Pre-op teaching, post-op complications, 20%
Care mobility aids, discharge planning
Page 2
,Q1. A patient with a history of chronic kidney disease (CKD) stage 4 presents with acute-onset atraumatic
shoulder pain, swelling, and limited range of motion. Radiographs reveal chondrocalcinosis and evidence of
calcium pyrophosphate dihydrate (CPPD) crystal deposition. Synovial fluid analysis shows positively
birefringent rhomboid crystals under polarized light microscopy. Which of the following best explains the
underlying pathophysiology of this presentation?
A. Uric acid crystal deposition due to impaired renal excretion leading to monosodium urate crystals
B. Calcium pyrophosphate crystal deposition facilitated by altered calcium and pyrophosphate metabolism in
CKD
C. Hydroxyapatite crystal deposition secondary to secondary hyperparathyroidism from CKD
D. Basic calcium phosphate crystal deposition due to elevated serum phosphate levels
Correct Answer: B. Calcium pyrophosphate crystal deposition facilitated by altered calcium and
pyrophosphate metabolism in CKD
Rationale: CPPD deposition disease (pseudogout) is associated with conditions like CKD, hyperparathyroidism,
and hemochromatosis. In CKD, reduced renal clearance of pyrophosphate leads to elevated levels, promoting
calcium pyrophosphate crystal formation. Option A describes gout (monosodium urate crystals, negatively
birefringent). Option C refers to hydroxyapatite deposition, often seen in calcific tendinitis. Option D is incorrect;
basic calcium phosphate crystals are not typically associated with CKD.
Why Wrong:
A - Uric acid crystals are negatively birefringent and associated with gout, not CPPD.
C - Hydroxyapatite crystals are not typically seen in CKD-related pseudogout.
D - Basic calcium phosphate crystals are associated with Milwaukee shoulder, not CKD.
Reference: Firestein, G.S., et al. (2021). Kelley & Firestein's Textbook of Rheumatology, 11th Ed., Ch. 107.
Q2. A patient with rheumatoid arthritis (RA) currently on methotrexate 20 mg weekly and sulfasalazine 2 g
daily continues to have 6 swollen and 8 tender joints, morning stiffness >1 hour, and an elevated CRP. The
patient has no history of tuberculosis or hepatitis. According to current ACR guidelines for RA management,
which of the following is the most appropriate next step?
A. Add hydroxychloroquine 400 mg daily
B. Switch from methotrexate to leflunomide 20 mg daily
C. Add a tumor necrosis factor (TNF) inhibitor such as adalimumab
D. Increase methotrexate dose to 25 mg weekly and continue sulfasalazine
Correct Answer: C. Add a tumor necrosis factor (TNF) inhibitor such as adalimumab
Rationale: The patient has moderate-to-high disease activity despite combination conventional synthetic DMARDs
(csDMARDs). Current ACR guidelines recommend adding a biologic DMARD (bDMARD), such as a TNF
inhibitor, in patients with inadequate response to csDMARDs. Option A would be appropriate for mild disease.
Option B is a switch within csDMARDs, but the patient has already failed combination therapy. Option D is
reasonable but the patient is already on a moderate dose; increasing methotrexate may not suffice.
Why Wrong:
A - Hydroxychloroquine is typically used for mild RA or in early disease, not after failure of combination
csDMARDs.
B - Switching to another csDMARD is less effective than adding a bDMARD in moderate-to-high disease
activity.
D - Increasing methotrexate is an option but less likely to achieve remission compared to adding a bDMARD.
Reference: Singh, J.A., et al. (2021). 2021 American College of Rheumatology Guideline for the Treatment of
Rheumatoid Arthritis. Arthritis Care & Research.
Page 3
, Q3. A patient with a history of osteoporosis, on denosumab 60 mg every 6 months for the past 3 years,
presents with a low-trauma vertebral compression fracture. Dual-energy x-ray absorptiometry (DXA) shows
a T-score of -3.2 at the lumbar spine, unchanged from 2 years ago. Which of the following is the most
appropriate management?
A. Continue denosumab and add teriparatide 20 mcg daily
B. Switch from denosumab to zoledronic acid 5 mg annually
C. Continue denosumab and add raloxifene 60 mg daily
D. Discontinue denosumab and start romosozumab 210 mg monthly
Correct Answer: A. Continue denosumab and add teriparatide 20 mcg daily
Rationale: The patient has sustained a fragility fracture despite denosumab therapy with stable BMD. Adding teriparatide (an
anabolic agent) to ongoing denosumab is recommended to improve bone strength. Option B is not indicated as denosumab has
not failed; switching to zoledronic acid may be considered if denosumab is discontinued, but the fracture occurred on therapy.
Option C: raloxifene is for vertebral fracture prevention in postmenopausal women but not for treatment of fracture on
therapy. Option D: romosozumab is an anabolic agent but is not typically added to denosumab; it is used as initial therapy in
high-risk patients.
Why Wrong:
B - Switching to zoledronic acid is not indicated as the patient is stable on denosumab; the fracture suggests need for
additional therapy.
C - Raloxifene is not indicated for treatment of fracture in patients already on denosumab.
D - Romosozumab is not typically used as add-on to denosumab; it is an initial therapy for high-risk patients.
Reference: Camacho, P.M., et al. (2020). American Association of Clinical Endocrinologists/American College of
Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis.
Endocrine Practice.
Q4. A patient with a history of type 2 diabetes and peripheral neuropathy presents with a painless, swollen,
and erythematous right foot after a minor twist. X-ray shows subtle osteopenia and joint space narrowing in
the midfoot, but no fracture. MRI reveals bone marrow edema and subchondral cysts in the tarsometatarsal
joints. Which of the following is the most likely diagnosis?
A. Septic arthritis of the midfoot
B. Charcot neuroarthropathy (neuropathic osteoarthropathy)
C. Acute gout flare involving the midfoot
D. Stress fracture of the metatarsals
Correct Answer: B. Charcot neuroarthropathy (neuropathic osteoarthropathy)
Rationale: Charcot neuroarthropathy is a progressive degenerative condition seen in patients with peripheral
neuropathy, often diabetes. It presents with a painless, swollen, erythematous foot, and MRI findings of bone
marrow edema, subchondral cysts, and joint destruction. Septic arthritis (A) typically presents with severe pain and
systemic signs. Gout (C) is usually painful and associated with hyperuricemia. Stress fracture (D) would show a
fracture line on imaging.
Why Wrong:
A - Septic arthritis is painful and associated with systemic signs; MRI would show joint effusion and abscess.
C - Gout is painful and typically has elevated uric acid; MRI findings differ.
D - Stress fracture would show a fracture line, not subchondral cysts.
Reference: Rogers, L.C., et al. (2020). The Charcot Foot: A Practical Guide. Journal of the American Podiatric
Medical Association.
Q5. A patient presents with acute onset of severe low back pain radiating to the left buttock and posterior
thigh. Straight leg raise test is positive on the left at 30 degrees. Neurologic exam reveals decreased sensation
over the lateral left foot and ankle, and mild weakness of left ankle plantarflexion. Which nerve root is most
likely affected?
Page 4
